Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.35 0.74 (3.42%) Market Cap: 1.59 Bil Enterprise Value: 1.33 Bil PE Ratio: 203.18 PB Ratio: 3.66 GF Score: 62/100

Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 01:40PM GMT
Release Date Price: $14.19 (+3.28%)
Kyuwon Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Hi. Good morning, everyone. We will continue with the next session, which is Kiniksa Pharmaceuticals. Please note that this session will be audio only. And with that, I'm pleased to turn it over to CEO, Sanj Patel, who will kick it off with some introductory remarks. Sanj?

Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board

Thanks, Paul. Good morning, and thanks, obviously, to Goldman Sachs for hosting us today. With me on the call are John Paolini, our Chief Medical Officer; Ross Moat, the ARCALYST General Manager and Head of Commercial; and Mark Ragosa, who's our Chief Financial Officer.

As always, please note that we will be making forward-looking statements today that are subject to both risks and uncertainties. A review of these statements and risk factors are found under the heading of Risk Factors in our SEC filings.

We are happy to have the opportunity today to discuss our recent approval and launch of ARCALYST in recurrent

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot